Generic Aphexda Availability
Last updated on May 7, 2025.
Aphexda is a brand name of motixafortide, approved by the FDA in the following formulation(s):
APHEXDA (motixafortide acetate - powder;subcutaneous)
-
Manufacturer: AYRMID PHARMA
Approval date: September 8, 2023
Strength(s): EQ 62MG BASE/VIAL [RLD]
Is there a generic version of Aphexda available?
No. There is currently no therapeutically equivalent version of Aphexda available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aphexda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Composition of BL-8040
Patent 12,257,285
Issued: March 25, 2025
Inventor(s): Halbfinger; Efrat et al.
Assignee(s): BioLineRx Ltd. (Modiln, IL); Biokine Therapeutics Ltd. (Nes Ziona, IL)A composition comprising BL-8040 (SEQ ID NO: 1) is disclosed herein, which may be for use in treating a condition treatable by BL-8040. The composition further comprises at least one compound characterized by a relative retention time of from 0.86 to 0.88 and/or a relative retention time of from 0.71 to 0.73 (wherein a relative retention time of BL-8040 is 1) under conditions described herein.
Patent expiration dates:
- December 29, 2041✓
- December 29, 2041
-
Composition of BL-8040
Patent 12,268,725
Issued: April 8, 2025
Inventor(s): Halbfinger; Efrat et al.
Assignee(s): BioLineRx Ltd. (Modiln, IL); Biokine Therapeutics Ltd. (Nes Ziona, IL)A composition comprising BL-8040 (SEQ ID NO: 1) is disclosed herein, which may be for use in treating a condition treatable by BL-8040. The composition further comprises at least one compound characterized by a relative retention time of from 0.86 to 0.88 and/or a relative retention time of from 0.71 to 0.73 (wherein a relative retention time of BL-8040 is 1) under conditions described herein.
Patent expiration dates:
- December 29, 2041✓
- December 29, 2041
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 8, 2028 - NEW CHEMICAL ENTITY
- September 8, 2030 - TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
More about Aphexda (motixafortide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: hematopoietic stem cell mobilizer
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
Dexamethasone
Dexamethasone is used to treat inflammatory conditions such as allergies, skin conditions ...
Darzalex
Darzalex (daratumumab) is a target therapy used to treat multiple myeloma. Includes DARZALEX uses ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
